Hepatic Carcinoma Clinical Trial
Official title:
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
The goal of this double-blind clinical trial is to compare the efficacy of octreotide versus placebo in laparoscopic hepatectomy surgery in patients diagnosed with resectable hepatocarcinoma or liver metastases. The main questions it aims to answer are: - Decrease in intraoperative bleeding measured in ml of blood lost. - Decrease in the need for blood transfusion and use of intraoperative vasoactive drugs. Participants will receive octreotide or placebo after signing the informed consent form.
The drug will be administered during surgery, after anesthetic induction, and will be withdrawn at the end of surgery before leaving the operating room. The patient will not receive any visit or require the performance of any other additional tests that are performed in the usual clinical practice. The monthly follow-up will coincide with the medical check-up and control analytical data will be taken. Subsequently, an attempt will be made to contact with the patient 3 months after surgery. The duration of participation of each participant in the trial will therefore be about 3 months after surgery. The intervention group will receive a loading dose of octreotide (100 mcgr) diluted in 100 ml of SSF to be given in half an hour and after that a continuous perfusion of 25 mcgr/h will be started until the end of the surgery. The pharmaceutical form to be used is Sandostatin. The control group will receive SSF as a placebo in the same sequence, first a loading dose in half an hour and then a continuous infusion of 25 mcgr/h until the end of surgery. and then a continuous infusion until the end of the surgery. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03253250 -
The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
|
Phase 4 | |
| Terminated |
NCT01760616 -
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
|
Phase 4 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Not yet recruiting |
NCT03149523 -
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
|
N/A | |
| Recruiting |
NCT05009550 -
ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation
|
N/A | |
| Recruiting |
NCT06342414 -
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
|
||
| Recruiting |
NCT03132740 -
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
|
||
| Completed |
NCT03164382 -
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Completed |
NCT03572582 -
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT04266548 -
Arterial Base Fluorescence Segmental Positive Staining
|
N/A | |
| Recruiting |
NCT03013712 -
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01350726 -
Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan
|
N/A | |
| Completed |
NCT06245798 -
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
|
||
| Recruiting |
NCT06311396 -
Development of a Neuronal Microscope
|
N/A | |
| Recruiting |
NCT04220944 -
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
|
Phase 1 | |
| Completed |
NCT02352935 -
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
|
N/A | |
| Completed |
NCT02332551 -
Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder
|
N/A | |
| Completed |
NCT02834780 -
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06182865 -
A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy
|
N/A | |
| Completed |
NCT05007548 -
to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve
|
Phase 2 |